BRD4 Ligand

(S)-JQ-35-Boc is a BRD4 ligand. (S)-JQ-35-Boc can be used to synthesize BRD4 degrader RAJQ14 (HY-181495). RAJQ14 can be used for cancer research.

PROTAC BET-binding moiety 2 is an inhibitor of BET bromodomain.

Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1).

Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC₅₀ of 10 nM, and with a K_i of 2.3 nM. Desmethyl-QCA276 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

PROTAC BRD4 ligand-4 is a BRD4 ligand, which can be used to synthesize PROTAC BRD4 Degrader-37 (HY-175225).

BRD3/BRD4-L ligand-2 is a BRD3/BRD4-L ligand. BRD3/BRD4-L ligand-2 serves as a ligand for the target protein in the design and development of PROTAC BRD3/BRD4-L degraders, such as PROTAC BRD3/BRD4-L degrader-2 (HY-149948). BRD3/BRD4-L ligand-2 can be used in cancer research.

QS-57 is a heterobifunctional targeted protein localization (TPL) agent. QS-57 binds to BRD4 via its JQ1 domain and covalently targets 14-3-3σ to form a ternary complex. QS-57 sequesters nuclear BRD4 in the cytoplasm, impairing the nuclear transcriptional regulatory function mediated by BRD4. QS-57 significantly reduces the nuclear BRD4 protein level and increases the cytoplasmic BRD4 protein abundance in cancer cells. QS-57 can be used for research on breast cancer and colorectal cancer.

CBP/p300/BRD4 ligand-1 is a small-molecule inhibitor targeting CBP, p300, and BRD4. CBP/p300/BRD4 ligand-1 competitively binds to the functional domains of target proteins without disrupting key interactions. CBP/p300/BRD4 ligand-1 can be used for the construction of dual-target PROTAC degraders (HY-181758) in studies related to prostate cancer and other cancers.

BRD4 ligand 16 is a BRD4 ligand. BRD4 ligand 16 can serve as a ligand for the target protein in the synthesis of BRD4 PROTAC degraders, such as PROTAC BRD4 Degrader-17 (HY-143328). BRD4 ligand 16 is suitable for use in cancer research.

FLT3/JAK2/BRD4 ligand-1 is a FLT3/JAK2/BRD4 ligand. FLT3/JAK2/BRD4 ligand-1 can be used for synthesis PROTAC FLT3/JAK2/BRD4 Degrader-1(HY-175610).

BRD4 ligand 15 (compound 5) is a BRD4 ligand and alkyne-modified chalcone derivative, which serves as a building block for the synthesis of BRD4-targeting PROTAC TKP-5 (HY-182370).

PROTAC BRD4 ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). PROTAC BRD4 ligand-3 can be used for synthesis PROTAC BRD4 Degrader-27 (HY-162875).

PROTAC BRD4 ligand-2 is a ligand for target BRD4 protein for PROTAC CFT-2718.

BRD4 ligand 13 is a BRD4 ligand that can be used for the synthesis of PROTACs, such as Cath-L-dBET1 (HY-173257). BRD4 ligand 13 is a target protein ligand-conjugate that can be used for the synthesis of PROTACs, such as SJH1-51B (HY-162240).

BRD4 ligand 10 is a PROTAC target protein ligand. BRD4 ligand 10 can be used to synthesize PROTAC BRD4 Degrader-49 (HY-185854).